14th International HLA and Immunogenetics Workshop: report on the Prospective Chronic Rejection Project

Area of Science:

• Immunology
• Transplantation Medicine
• Clinical Diagnostics

Background:

• Post-transplant antibodies are a significant concern in organ transplantation.
• Predictive markers for chronic graft failure are crucial for improving patient outcomes.

Purpose of the Study:

• To investigate the predictive value of post-transplant human leukocyte antigen (HLA) antibodies for chronic graft failure.
• To analyze the impact of major histocompatibility complex class I-related chain A (MICA) antibodies on graft outcomes.

Main Methods:

• An international collaborative study involving 45 transplant centers and 5219 patient sera.
• Testing for HLA and MICA antibodies using enzyme-linked immunosorbent assay, flow cytometry, and Luminex.
• Correlation analysis between antibody presence and graft rejection or patient death.

Main Results:

• HLA antibodies were detected in 27.2% of kidney, 23.6% of liver, 52.7% of heart, and 21.7% of lung transplant recipients.
• MICA antibodies were found in 15% of kidney, 30% of heart, and 31% of liver transplant patients.
• Kidney patients with HLA antibodies showed a significantly higher rate of graft rejection (7.3% vs. 1.7%, P=0.8 x 10(-17)).

Conclusions:

• Post-transplant HLA antibodies are confirmed as predictors of chronic graft failure.
• The presence of HLA antibodies is associated with an increased risk of chronic graft rejection.
• MICA antibodies also play a role in transplant outcomes, particularly in heart and liver recipients.